VBI Vaccines (NASDAQ:VBIV) Shares Down 6.3%

Shares of VBI Vaccines Inc (NASDAQ:VBIV) fell 6.3% during trading on Monday . The company traded as low as $0.59 and last traded at $0.60, 3,644,694 shares were traded during trading. An increase of 159% from the average session volume of 1,406,737 shares. The stock had previously closed at $0.64.

A number of brokerages have recently commented on VBIV. Zacks Investment Research lowered VBI Vaccines from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. ValuEngine upgraded VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The firm has a market capitalization of $103.32 million, a P/E ratio of -0.62 and a beta of 0.46. The company has a quick ratio of 0.92, a current ratio of 0.95 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $0.56 and a 200-day moving average price of $1.12.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.60 million. VBI Vaccines had a negative return on equity of 73.80% and a negative net margin of 1,582.45%. As a group, sell-side analysts forecast that VBI Vaccines Inc will post -0.46 EPS for the current year.

In related news, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $0.50 per share, with a total value of $10,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeff Baxter bought 150,000 shares of the business’s stock in a transaction on Monday, September 30th. The stock was bought at an average cost of $0.50 per share, for a total transaction of $75,000.00. Following the purchase, the chief executive officer now directly owns 608,255 shares of the company’s stock, valued at approximately $304,127.50. The disclosure for this purchase can be found here. Insiders acquired 30,212,000 shares of company stock worth $15,105,440 over the last quarter. Company insiders own 10.50% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. acquired a new position in VBI Vaccines in the second quarter valued at about $25,000. Citadel Advisors LLC bought a new stake in shares of VBI Vaccines in the second quarter worth about $31,000. Bank of Montreal Can increased its holdings in shares of VBI Vaccines by 71.8% in the second quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 15,717 shares in the last quarter. Susquehanna International Group LLP bought a new stake in shares of VBI Vaccines in the second quarter worth about $58,000. Finally, Weil Company Inc. increased its holdings in shares of VBI Vaccines by 228.6% in the second quarter. Weil Company Inc. now owns 71,875 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 50,000 shares in the last quarter. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: What is the formula for the cash asset ratio?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.